ResMed Research and Development Expenses 2010-2024 | RMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ResMed annual research and development expenses for 2024 were $0.308B, a 6.91% increase from 2023.
ResMed annual research and development expenses for 2023 were $0.288B, a 13.43% increase from 2022.
ResMed annual research and development expenses for 2022 were $0.254B, a 12.56% increase from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ResMed annual research and development expenses for 2024 were $0.308B, a 6.91% increase from 2023.
ResMed annual research and development expenses for 2023 were $0.288B, a 13.43% increase from 2022.
ResMed annual research and development expenses for 2022 were $0.254B, a 12.56% increase from 2021.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$205.5B
Stryker (SYK)	$138.7B
Boston Scientific (BSX)	$121.5B
Medtronic (MDT)	$113.7B
EssilorLuxottica (ESLOY)	$104.2B
Haleon (HLN)	$48.6B
Lonza Group Ag (LZAGY)	$45.9B
Koninklijke Philips (PHG)	$29.3B
Terumo (TRUMY)	$27.8B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.3B
Insulet (PODD)	$16.5B
Smith & Nephew SNATS (SNN)	$13.5B
Bio-Rad Laboratories (BIO)	$9.3B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.3B
ICU Medical (ICUI)	$4.3B
Haemonetics (HAE)	$3.9B
TG Therapeutics (TGTX)	$3.9B
GN Store Nord (GNNDY)	$3.8B
Perrigo (PRGO)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B
LeMaitre Vascular (LMAT)	$2B